Araştırma Makalesi

Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study

Cilt: 46 Sayı: 2 29 Haziran 2024
PDF İndir
TR EN

Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study

Abstract

Uric acid (UA) acts as a richly available water-soluble antioxidant, contributing to approximately two-thirds of the overall free-radical-scavenging activity in human serum. It is discharged from damaged cells during the preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study assessed how pretransplantation uric acid levels influence survival and mortality in allo-HSCT patients. In a retrospective analysis of 267 patients with hematologic diseases who underwent allo-HSCT, uric acid levels were documented on the day of allo-HSCT (day 0). Patients were divided into two cohorts based on their pretransplant uric acid levels: those at or below 4.4 mg/dL and those above 4.4 mg/dL. Among them, 153 (57.3%) were male, and 114 (42.7%) were female, with a median age of 31 years (ranging from 13 to 66). Those with serum uric acid levels of 4.4 mg/dL or lower exhibited notably poorer overall survival (OS) and disease-free survival (DFS) compared to those surpassing 4.4 mg/dL (p=0.032 and p=0.045, respectively). Our findings indicate an interrelation between low pretransplant serum uric acid levels and reduced survival rates in allo-HSCT patients. Further exploration into potential mechanisms, such as compromised antioxidative capacity in hypouricemia, may establish uric acid as a promising prognostic marker in allo-HSCT.

Keywords

Kaynakça

  1. Arcangelo L, Margherita N, Francesca M, Raffaele LR, Emanuela T. Hematopoietic Stem Cell Transplantation: A Bioethical Lens. Stem Cells International 2017;2017: 1286246.
  2. Lu Z, Shanquan C, Panxin Y, Hongcui C, Lanjuan L. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graf-versus host disease. Stem Cell Research & Therapy. 2019;21;10(1):182.
  3. Yao-Chung L, Sheng-Hsuan C, Nai-Wen F, et al. Prognostic Factors on the Graft- versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation. Stem Cells International 2016. 5143071.
  4. John R W, Jack H, John W H. Wingard JR, Hsu JH, Heimenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect. Dis. Clin. North. Am. 2010;24(2):257-72. https://doi:10.1016/j.idc.2010.01.010
  5. Ugur S, Selami KT, Pinar AA, Atilla E, Taner D. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. Journal of Infection and Chemotherapy 2016;22(8):505-14. https://doi: 10.1016/j.jiac.2016.05.006.
  6. Navneet SM. Long Term Complications After Hematopoietic Cell Transplantation. Hematol Oncol Stem Cell Ther 2017;10(4):220-27. https://doi:10.1016/j.hemonc.2017.05.009
  7. Akifumi K, Yusuke N, Yasuka M. et al. Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis. Mediators of Inflammation 2016;2016:8603134. https://doi: 10.1155/ 2016/8603164
  8. Cristine E B, Joshua M H. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. Journal of Physiology 2004;16;555:589-606. https://doi:10.1113/jphysiol.2003. 055913

Ayrıntılar

Birincil Dil

İngilizce

Konular

Tıp Eğitimi

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

29 Haziran 2024

Gönderilme Tarihi

30 Ocak 2024

Kabul Tarihi

9 Haziran 2024

Yayımlandığı Sayı

Yıl 2024 Cilt: 46 Sayı: 2

Kaynak Göster

AMA
1.Mandacı Şanlı N, Keklik M, Ünal A. Role of Uric Acid Levels as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Single-Center Study. CMJ. 2024;46(2):121-128. doi:10.7197/cmj.1428410

Cited By